Glenmede Trust Co. NA Buys 27,673 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Glenmede Trust Co. NA raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 163.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 44,554 shares of the medical equipment provider's stock after purchasing an additional 27,673 shares during the period. Glenmede Trust Co. NA's holdings in Zimmer Biomet were worth $4,810,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter valued at $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet during the third quarter valued at about $31,000. Family Firm Inc. purchased a new position in shares of Zimmer Biomet in the second quarter valued at about $33,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the third quarter worth about $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Zimmer Biomet during the second quarter worth about $43,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Up 0.1 %

Shares of ZBH stock traded up $0.08 during trading hours on Friday, reaching $112.10. 504,058 shares of the stock were exchanged, compared to its average volume of 1,527,881. The firm has a market capitalization of $22.32 billion, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 2.06 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The company's 50-day moving average price is $107.29 and its 200-day moving average price is $109.38. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the business earned $1.65 earnings per share. The company's revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Analyst Ratings Changes

ZBH has been the topic of a number of research analyst reports. Evercore ISI lowered their price target on Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating on the stock in a report on Tuesday, October 1st. Robert W. Baird lowered their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a report on Thursday, August 8th. BTIG Research cut their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating for the company in a research note on Thursday, October 3rd. Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Finally, TD Cowen cut their price objective on Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating for the company in a research report on Friday, September 6th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $123.22.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.